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OBJECTIVES The goal of this study was to test the hypothesis that growth hormone (GH) administration
to patients with chronic heart failure (CHF) corrects their vascular dysfunction.
BACKGROUND Endothelial dysfunction is a prominent feature of CHF. Recent evidence indicates that GH
plays a role in vascular reactivity.
METHODS We studied vascular reactivity in 16 patients with CHF (New York Heart Association class
II to III) before and after three months of GH (4 IU subcutaneously every other day) or
placebo administration in a randomized, double-blind trial. We measured forearm blood flow
(FBF) by strain-gauge plethysmography during intrabrachial, graded infusion of acetylcholine
(ACh) and sodium nitroprusside (NP). We also measured the forearm balance of nitrite and
cyclic guanosine monophosphate (cGMP) before and during ACh infusion. Maximal oxygen
uptake (VO2max) was measured by breath-to-breath respiratory gas analysis.
RESULTS Before treatment, the response of FBF to ACh was flat (p  NS). Growth hormone, but not
placebo, greatly improved this response (p  0.03) and, concomitantly, increased the forearm
release of nitrite and cGMP (p  0.05). Growth hormone also potentiated the FBF response
to NP (p  0.013). Growth hormone interacted with ACh response (p  0.01) but not with
the response to NP (p  NS). Accordingly, GH enhanced the slope of the dose-response
curve to ACh (p  0.05) but not to NP. The VO2max increased significantly after GH
treatment (20 2 and 26  2 ml ·Kg1· min1 before and after GH treatment, respectively,
p  0.05) but not after placebo.
CONCLUSIONS A three-month treatment with GH corrected endothelial dysfunction and improved
non-endothelium-dependent vasodilation in patients with CHF. The data highlight the
potential role of GH in the progression of congestive heart failure. (J Am Coll Cardiol
2002;39:90–5) © 2002 by the American College of Cardiology
The vascular endothelium plays a relevant role in the control
of many functions, including fibrinolysis, thrombosis, in-
flammation, vascular growth and vascular tone (1,2). To
regulate the vascular tone, the endothelium releases several
vasoactive substances, which exert either vasoconstrictive
(i.e., endothelin) or vasodilating action (i.e., nitric oxide
[NO]). Nitric oxide is synthesized from L-arginine and
oxygen by the endothelial isoform of NO synthase. Once
produced in the endothelial cells, NO diffuses into the
subadjacent smooth muscle cells where it stimulates the
conversion of GTP to cyclic guanosine monophosphate
(cGMP) (1). This induces vascular relaxation by reducing
the intracellular concentration of calcium (1).
A distinct feature of patients affected by chronic heart
failure (CHF) is the impaired vascular reactivity (3,4). This
consists of attenuated vasodilation in response to acetylcho-
line (ACh), pointing to an endothelium-dependent defect.
On the other hand, the response to nitroprusside (NP), a
direct NO donor and endothelium-independent vasodilator,
appears to be largely preserved (5,6), suggesting that in
CHF a loss of bioactive endothelial NO is responsible for
the vascular dysfunction.
The impaired endothelium-dependent vasodilation in
CHF contributes to the elevated peripheral vascular resis-
tance (PVR), which further aggravates left ventricular (LV)
afterload and impairs physical exercise capacity. For these
reasons, endothelial dysfunction is relevant to heart failure
progression, and consequently, it is regarded as one of the
therapeutic targets. Indeed, there have been several attempts
to correct the endothelium dysfunction of CHF, including
oral arginine supplementation, administration of antioxi-
dants and physical exercise (7–9).
Recent evidence indicates that growth hormone (GH)
plays a role in the regulation of PVR and vascular reactivity.
Patients with GH deficiency show increased PVR and reduced
systemic generation of NO and cGMP (10,11). These abnor-
malities are reversed by specific replacement therapy with GH
(11). Growth hormone deficiency is also associated with
impaired vascular reactivity due to a complex defect that
involves the entire pathway of NO-mediated vasodilation (12).
Given the role of GH in the regulation of PVR and
vascular reactivity, the present study was designed to test the
hypothesis that GH administration to patients with CHF,
as an addition to their background therapy, is able to correct
their abnormal vascular reactivity.
METHODS
Patients and experimental design. The study was per-
formed on 16 patients with CHF due to idiopathic (n 11)
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or ischemic (n  5) dilated cardiomyopathy (Table 1). The
inclusion criteria were: 1) echocardiographic evidence of LV
ejection fraction 40% and LV internal diameter 58 mm;
2) clinical evidence of CHF despite conventional therapy;
and 3) stable clinical conditions for the previous three
months. Twelve patients were in New York Heart Associ-
ation (NYHA) class II and four in NYHA class III.
Exclusion criteria were myocardial infarction or treatment
of coronary artery disease by interventional procedures for
the previous six months, unstable angina, major arrhythmias
(Lown class IV), systemic hypertension, significant valvu-
lar heart disease, hypertrophic cardiomyopathy and chronic
alcoholism. Eight patients were treated for three months
with recombinant human GH at a dose of 4 IU given
subcutaneously every other day, whereas eight patients
received placebo, according to a randomized, double-blind
design. Any other cardiovascular medication remained un-
changed throughout the study period. Growth hormone
(Humatrope), placebo and the injection system (Humatro-
Pen II) were provided by Eli Lilly, Florence, Italy. Written
informed consent was obtained from each patient, and the
study was approved by the Ethics Committee of the
University Federico II.
Procedures. Each patient attended for two vascular studies,
performed before and at the end of the three-month
treatment period. All patients were studied in the morning,
after a 12 to 15 h overnight fast, in a quiet room kept at
22°C to 24°C, as previously described (12). Briefly, a plastic
cannula (20G) was inserted into the brachial artery of the
nondominant arm under local anesthesia and used for the
infusion of the test substances, the monitoring of arterial
blood pressure and heart rate and arterial blood sampling. In
the same arm, a second plastic cannula was introduced into
a large antecubital vein to obtain venous blood samples.
Forearm blood flow (FBF) was measured in both forearms
by strain gauge plethysmography, with a calibrated mercury-
in-silastic strain gauge applied around the forearm and
connected to a plethysmography (Hokanson 045 EC4,
P.M.S. Instruments, Berks, United Kingdom) associated
with a MacLab computer. Both arms were supported
slightly above the heart level. Each subject underwent the
following stepwise infusions into the brachial artery: 1)
ACh, at the rate of 30, 45 and 60 g ·l of forearm1·min1,
to assess endothelial-mediated vasodilation; 2) NP, a direct
NO donor, at the rate of 1, and 3 g ·l1·min1, to assess
non-endothelial-mediated vasodilation; and 3) L-N-
monomethylarginine (L-NMMA), a competitive analog of
L-arginine, at the rate of 1 mg·l1·min1. Each dose of the
test substances was infused for 5.5 min, and FBF was
measured during the last 1.5 min of infusion. A 30-min
washout was allowed between each substance infusion.
Blood samples were simultaneously taken from the arterial
and venous cannulas in the basal state and at the end of the
maximal dose of ACh to measure nitrate/nitrite and cGMP
concentrations. Forearm blood flow was measured simulta-
neously in both arms to ensure that no systemic effects
occurred during the experiment. Each FBF value represents
the mean of six consecutive measurements performed at 8-s
intervals.
Symptom-limited exercise test was performed according
to the Cornell-modified treadmill protocol (2-min step
increments), and maximal oxygen uptake (VO2max) was
measured by breath-to-breath respiratory gas analysis
(Benchmark Exercise Test System, Morgan, Bologna, Italy).
Analytical methods. Serum insulin-like growth factor I
(IGF-I) concentration was measured by radioimmunoassay.
Nitrite concentration was measured in plasma samples using
EDTA as an anticoagulant. After collection, blood samples
were immediately centrifuged at 2,000 rpm at 4°C and
plasma stored at 20°C. Before assay, plasma was ultrafil-
tered through a 10kDa molecular weight cut-off filter
(Centricon 10, Millipore, Bedford, Massachusetts). Total
plasma nitrite and nitrate were measured using a colorimet-
Abbreviations and Acronyms
ACh  acetylcholine
cGMP  cyclic guanosine monophosphate
CHF  chronic heart failure
FBF  forearm blood flow
GH  growth hormone
IGF-I  insulin-like growth factor I
L-NMMA  L-N-monomethylarginine
LV  left ventricular
NYHA  New York Heart Association
NO  nitric oxide
NP  sodium nitroprusside
PVR  peripheral vascular resistance
VO2max  maximal oxygen uptake
Table 1. Clinical and Biochemical Characteristics of
the Patients
Baseline End of Study
Placebo
(n  8)
GH
(n  8)
Placebo
(n  8)
GH
(n  8)
Gender (M/F) 6/2 6/2 — —
Age (yr) 56  4 53  4 — —
Etiology (ID/IS) 5/3 6/2
BMI (kg/m2) 26  1.1 27  1.5 26  1.1 27  1.4
Serum IGF-I
(ng/ml)
149  25 143  16 159  28 295  31*†
Plasma glucose
(mg/dl)
96  4 97  6 95  5 102  4
Total cholesterol
(mg/dl)
196  4 188  5 200  7 183  5
Triglycerides
(mg/dl)
160  20 148  23 156  21 131  17
SBP (mm Hg) 124  5 128  6 120  3 118  2*
DBP (mm Hg) 73  3 74  2 71  2 69  2*
Heart rate
(beats/min)
64  2 69  4 64  2 72  3
M  SE, *p 0.05 vs. baseline; †p 0.05 vs. placebo.
BMI  body mass index; DBP  diastolic blood pressure; GH  growth
hormone; ID  idiopathic; IGF-I  insulin-like growth factor I; IS  ischemic;
SBP  systolic blood pressure.
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ric kit (Cayman Chemical Co., Ann Arbor, Michigan).
Nitrate was converted to nitrite by nitrate reductase, and
then nitrite was assayed by the standard Greiss diazo-
reaction. All determinations were done in triplicate. The
data are referred to as nitrite concentration, but they reflect
the sum of nitrate and nitrite. For the determination of
cGMP, plasma samples were centrifuged at 4°C after the
addition of cold 6% trichloroacetic acid. Supernatants were
washed with five volumes of water-saturated diethyl ether
and dried under a stream of nitrogen at 60°C. The dried
extracts were dissolved in 0.5 mol/l acetate buffer, pH 5.8,
and acetylated by a mixture of acetic acid anhydride/
triethylamine. The cGMP content was measured in dupli-
cate with radioimmunoassay (Amersham International,
UK).
Calculations. The net forearm balance of nitrite and
cGMP was calculated by multiplying the plasma arterial-
venous concentration difference of each substrate by the
plasma flow. Therefore, a negative balance indicates sub-
strate release, whereas a positive balance indicates uptake.
Results are expressed as mean  SEM. The differences in
clinical and metabolic characteristics between the two pa-
tient groups and the effect of treatment within groups were
analyzed using the unpaired and the paired Student t test,
respectively. The data on vascular reactivity were analyzed
by a two-way repeated measures analysis of variance
(ANOVA) (SPSS, version 10.0, Chicago, Illinois), which
tested the effect of the vasodilating agent (ACh or NP), the
treatment effect (GH or placebo) and the interaction be-
tween them. Vascular reactivity data are expressed as abso-
lute values of FBF.
RESULTS
Table 1 shows the patients’ clinical and biochemical data.
No differences were observed between the two groups before
treatment. As expected, at the end of the treatment period,
IGF-I concentration was significantly higher in the GH-
treated group compared with the basal values and the
placebo group (p  0.01). Both systolic and diastolic blood
pressures were lowered by GH (p  0.05).
The results of the repeated-measures ANOVA for the
vascular reactivity data are summarized in Table 2. Before
treatment, the FBF response to ACh was flat in both groups
(Fig. 1). Treatment with placebo did not affect this response
(at the highest ACh dose, FBF was 4.7 0.9 and 5.9 1.3
ml·dl of forearm1·min1 before and after placebo, respec-
tively). In contrast, GH treatment greatly improved ACh-
mediated, endothelium-dependent vasodilation (p  0.03).
In response to the highest dose of ACh, FBF rose to 4.6 
1.9 and 14.7  4.2 ml·dl1·min1 before and after GH,
respectively.
Growth hormone also modified the pattern of the dose-
response curve to ACh, as shown by the significant inter-
action between GH and ACh (p  0.01). Accordingly, the
slope of the dose-response curve to ACh was enhanced by
GH (0.06  0.02 and 0.16  0.04 ml·dl1·min1 ·g1
before and after GH treatment, respectively; p  0.05).
Figure 2 illustrates forearm nitrite and cGMP balances
during ACh infusion. Before treatment, both groups of
patients were characterized by lack of forearm nitrite pro-
duction in response to ACh. After treatment, ACh did not
Table 2. Repeated Measures ANOVA for the Dose-response
Curves to ACh and NP
Growth
Hormone
(n  8)
Placebo
(n  8)
F
Value
p
Value
F
Value
p
Value
Response to ACh at baseline 2.18 NS 1.92 NS
Treatment effect 5.79 0.03 0.95 NS
Treatment  ACh interaction 5.99 0.01 0.67 NS
Response to NP at baseline 18.81 0.003 44.1 0.001
Treatment effect 8.00 0.013 0.21 NS
Treatment  NP interaction 2.51 NS 0.20 NS
The analysis was performed using the SPSS statistical package (version 10.0 for
windows).
ACh  acetylcholine; ANOVA  analysis of variance; NP  sodium nitroprus-
side.
Figure 1. Forearm blood flow response to acetylcholine (Ach) infusion in
placebo- and growth hormone (GH)-treated patients at baseline and at the
end of treatment. Data were analyzed by analysis of variance for repeated
measures. p  NS for the basal response to Ach; p  0.03 for the effect of
GH treatment; p  0.01 for the interaction between GH and ACh.
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induce any change in forearm nitrite release in the placebo
group. In contrast, in the GH-treated patients ACh caused
significant increase in forearm nitrite release (p  0.05).
Similarly, before treatment CHF patients were character-
ized by no response in forearm cGMP production to ACh.
In the GH-treated patients, but not in the placebo group,
ACh induced cGMP release by the forearm. This change
was of borderline significance (p  0.07).
As shown in Figure 3 and Table 2, in both groups of
patients NP elicited a vasodilatory response before treat-
ment. However, whereas in the placebo group this response
was similar before and after treatment, in the GH-treated
patients the increase of FBF was markedly potentiated (p 
0.013). At the highest dose of NP, FBF was 8.5  1.0 and
12.8  1.4 ml·dl1·min1 before and after GH treatment,
respectively.
Despite the significant treatment effect, GH had no effect
on the pattern of the response to NP, as indicated by the
lack of significant interaction between GH and NP. In
accordance, GH did not affect the slope of the dose-response
curve (2.1 0.32 and 3.0 0.41 ml·dl1·min1 ·g1 before
and after GH treatment, respectively; p  NS).
In Figure 4 the slopes of the dose-response curves to ACh
are plotted against the baseline IGF-I levels of each patient.
The data show a positive significant correlation between the
serum IGF-I level and the endothelial response (p 
0.0001).
The basal FBF was not different in the two study groups
and was unchanged by both placebo and GH treatment
(Fig. 1). The decrease of FBF after intrabrachial L-NMMA
infusion was 1.0  0.2 and 1.3  0.3 ml·dl1·min1 before
and after GH treatment, respectively (p  NS). A similar
response was observed in the placebo group (0.6  0.3 and
0.8  0.2 ml·dl1·min1 before and after placebo, respec-
tively (p  NS).
The VO2max increased significantly after GH treatment
(20  2 and 26  2 ml ·Kg1·min1 before and after GH
treatment, respectively, p  0.05). No significant change was
observed with placebo (22  2 and 24  2 ml ·Kg1·min1
before and after placebo, respectively, p  NS).
DISCUSSION
Our patients with CHF showed a flat response of FBF to
ACh infusion, attesting to their endothelial dysfunction, in
agreement with previous studies (3–5). This defect was
associated with the inability of ACh to induce the release of
nitrite and cGMP from the forearm vascular bed. Three
Figure 2. Forearm nitrite (upper panel) and cyclic guanosine monophos-
phate (cGMP) (lower panel) balance during intrabrachial acetlycholine
infusion in placebo- and growth hormone (GH)-treated patients at
baseline and at the end of treatment. *p  0.05 versus the corresponding
basal value; #0.1  p  0.05 versus the corresponding basal value. The
signs () and () indicate uptake and release, respectively.
Figure 3. Forearm blood flow response to sodium nitroprusside (NP)
infusion in the placebo- and growth hormone (GH)-treated patients at
baseline and at the end of treatment. Data were analyzed by analysis of
variance for repeated measures. p  0.005 for the basal response to NP;
p  0.013 for the effect of GH treatment; p  NS for the interaction
between GH and NP.
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months of therapy with human recombinant GH corrected
endothelial dysfunction, whereas no improvement was ob-
served in the placebo group. The restored endothelial
function was associated with significant release of nitrite and
cGMP from the forearm during ACh infusion. It is note-
worthy that normalization of vascular function by GH was
paralleled by improvement of VO2max during physical
exercise.
Vascular dysfunction in CHF. Previous studies have
shown that CHF is characterized by impairment of ACh-
mediated endothelial response, suggesting that a defect in
NO production by the endothelium is the mechanism
responsible for vascular dysfunction (3–5). However, direct
measurement of nitrite balance during ACh infusion in
patients with CHF was not performed. This study shows
that the forearm vasculature of patients with CHF does not
produce nitrite in response to ACh, thus providing direct
evidence that the defective endothelial function in CHF is
due to reduced bioactive NO. Our data also suggest that
GH corrects vascular reactivity by restoring one of the key
functions of endothelial cells, that is, NO production. The
fact that the restored response to ACh occurred in conjunc-
tion with simultaneous production of both NO and cGMP
supports a central role of NO in mediating the vascular
defect in CHF and its recovery after GH therapy. Interest-
ingly, in this study the improved vascular reactivity by GH
was associated with enhancement of exercise capacity, as
shown by the VO2max data. Given the key role of shear-
stress in the adaptive response of the vascular bed to physical
exercise, one may speculate that GH is likely to interfere
with the mechanism activated by shear-stress (13,14).
The improved vascular reactivity observed in our patients
after GH treatment was not due solely to an endothelial
component, but it also involved a non-endothelium-
mediated mechanism. Although the response to NP was
largely preserved in our patients before treatment, GH
therapy induced a substantial change in the vasodilating
response to NP. The mechanism by which GH affected this
response remains speculative. Insulin-like growth factor I
may act directly on the vascular smooth muscle cells by
influencing the intracellular Ca2 concentration (15) or
regulating the Na-K-ATPase activity (16). In addition,
it is well known that IGF-I stimulates smooth muscle cell
proliferation and angiogenesis (17–19). Interestingly, GH
was reported to increase the capillary density in patients
with GH deficiency and in animal models of heart failure
(20,21). Based on these findings, there is a temptation to
think that GH may improve vascular reactivity also by
inducing structural changes in the vascular bed.
Previous studies. Our findings are in line with previous
observations regarding the role of GH in the physiology of
the resistance vessels and vascular reactivity. In patients with
GH deficiency, the systemic generation of NO and cGMP
is reduced, whereas vascular reactivity is impaired and
vascular resistance is increased (11,12). After GH replace-
ment therapy, vascular homeostasis is normalized, and
concomitantly, the production of NO and cGMP is re-
stored, systemically and at the forearm level (11,12). Con-
sistent with our findings, a recent study of patients with
CHF showed low urinary nitrate and cGMP excretion that
was markedly increased by a three-month treatment with
GH (22). In that study and in the current one, the basal
IGF-I level was in the low physiologic range, in agreement
with the documented reduced activity of the GH/IGF-I
axis in patients with CHF (23). This observation raises the
question whether the impaired endothelial function ob-
served in CHF is, in part, accounted for by the low GH
activity. Support for this interpretation would be provided
by the striking similarity between CHF and GH deficiency
with regard to the altered vascular homeostasis and its
substantial correction after GH treatment. Consistent with
this line of reasoning is the striking positive correlation
between the IGF-I level and the slope of the dose response
curve to ACh (p  0.0001; Fig. 4). This correlation
remained significant as well when the patients treated with
GH were excluded from the analysis (p  0.02), which
supports the concept that the GH/IGF-I axis is likely to
play a role in the pathogenesis of endothelial dysfunction
and, consequently, in the progression of CHF, as previously
suggested (11,12,22,23).
Clinical implications. The present finding, that GH cor-
rects the abnormal vascular reactivity in CHF, may have
relevant clinical implications. Vascular dysfunction is one of
the factors involved in the progression of CHF by the
intervention of multiple mechanisms: 1) increased ventric-
ular afterload; 2) reduced coronary perfusion; 3) progression
of atherosclerotic lesions; 4) peripheral vascular remodel-
ling; 5) limited vascular reserve in the skeletal muscle and
Figure 4. Relation between the slopes of the dose response curves to
acetylcholine and the basal serum insulin-like growth factor I (IGF-I)
concentrations.
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consequent impaired exercise capacity; and 6) potential
interference with myocardial structure and function (24–
27). For these reasons, the endothelium is regarded as a
primary therapeutic target in heart failure (28). The present
finding that GH normalizes vascular reactivity by a complex
action on the entire NO-mediated pathway and improves
VO2max offers an additional mechanism in support of its
potentially beneficial effect in patients with CHF (29,30).
Reprint requests and correspondence: Dr. Luigi Sacca`, Medi-
cina Interna, Via Pansini 5, 80131 Napoli, Italy. E-mail: sacca@
unina.it.
REFERENCES
1. Celermajer DS. Endothelial dysfunction: does it matter? Is it revers-
ible? J Am Coll Cardiol 1997;30:325–33.
2. Petty RG, Pearson JD. Endothelium—the axis of vascular health and
disease. J R Coll Physicians 1989;23:92–101.
3. Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM.
Endothelium-dependent vasodilation is attenuated in patients with
heart failure. Circulation 1991;84:1589–96.
4. Drexler H, Hayoz D, Munzel T, et al. Endothelial function in chronic
congestive heart failure. Am J Cardiol 1992;69:1596–601.
5. Hirooka Y, Imaizumi T, Tagawa T, et al. Effects of L-arginine on
impaired acetylcholine-induced and ischemic vasodilation of the fore-
arm in patients with heart failure. Circulation 1994;90:658–68.
6. Katz SD. Mechanisms and implications of endothelial dysfunction in
congestive heart failure. Curr Opin Cardiol 1997;12:259–64.
7. Drexler H. Endothelial dysfunction: clinical implications. Prog Car-
diovasc Dis 1997;39:287–324.
8. Katz SD, Krum H, Kahn T, Knecht M. Exercise-induced vasodilation
in forearm circulation of normal subjects and patients with congestive
heart failure: role of endothelium-derived nitric oxide. J Am Coll
Cardiol 1996;28:585–90.
9. Rector TS, Bank AJ, Mullen KA, et al. Randomized, double-blind,
placebo-controlled study of supplemental oral L-arginine in patients
with heart failure. Circulation 1996;93:2135–41.
10. Fazio S, Cittadini A, Sabatini D, et al. Growth hormone and heart
performance: a novel mechanism of cardiac wall stress regulation in
humans. Eur Heart J 1997;18:340–7.
11. Bo¨ger RH, Skamira C, Bode-Bo¨ger SM, Brabant G, von zur Mu¨hlen
A, Frolich JC. Nitric oxide may mediate the hemodynamic effects of
recombinant growth hormone in patients with acquired growth hor-
mone deficiency: a double-blind, placebo-controlled study. J Clin
Invest 1996;98:2706–13.
12. Capaldo B, Guardasole V, Pardo F, et al. Abnormal vascular reactivity
in growth hormone deficiency. Circulation 2001;103:520–4.
13. Katz SD. The role of endothelium-derived vasoactive substances in the
pathophysiology of exercise intolerance in patients with congestive
heart failure. Prog Cardiovasc Dis 1995;38:23–50.
14. Joannides R, Haefeli WE, Linder L, et al. Nitric oxide is responsible
for flow-dependent dilation of peripheral conduit arteries in vivo.
Circulation 1995;92:1314–9.
15. Ren J, Walsh MF, Hamaty M, Sowers JR, Brown R. Altered inotropic
response to IGF-I in diabetic rat heart: influence of intracellular Ca
and NO. Am J Physiol 1998;275:823–30.
16. Standley PR, Zhang F, Zayas RM, et al. IGF-I regulation of
Na-K-ATPase in rat arterial smooth muscle. Am J Physiol 1997;
273:113–21.
17. Chen Y, Capron L, Magnusson JO, Wallby LA, Arnqvist HJ.
Insulin-like growth factor-1 stimulates vascular smooth muscle cell
proliferation in rat aorta in vivo. Growth Hormone IGF Res 1998;8:
299–303.
18. Du J, Delafontaine P. Inhibition of vascular smooth muscle cell growth
through antisense transcription of a rat insulin-like growth factor I
receptor cDNA. Circ Res 1995;76:963–72.
19. Florini JR, Ewton DZ, Coolican SA. Growth hormone and insulin-
like growth factor system in myogenesis. Endocrine Rev 1996;17:481–
517.
20. Hellstrom A, Svensson E, Carlsson B, Niklasson A, Albertsson-
Wikland K. Reduced retinal vascularization in children with growth
hormone deficiency. J Clin Endocrinol Metab 1999;84:795–8.
21. Houck WV, Pan LC, Kribbs SB, et al. The effects of growth hormone
supplementation on left ventricular and myocyte function with the
development of congestive heart failure. Circulation 1999;100:2003–9.
22. Osterziel KJ, Bode-Bo¨ger SM, Stro¨hm O, et al. Role of nitric oxide in
the vasodilator effect of recombinant human growth hormone in
patients with dilated cardiomyopathy. Cardiovasc Res 2000;14:447–
53.
23. Giustina A, Lorusso R, Borghetti V, Bugari G, Misitano V, Alfieri O.
Impaired spontaneous growth hormone secretion in severe dilated
cardiomyopathy. Am Heart J 1996;131:620–2.
24. Ramsay MW, Goodfellow J, Jones CJH, Luddington LA, Lewis MJ,
Henderson AH. Endothelial control of arterial distensibility is im-
paired in chronic heart failure. Circulation 1995;92:3212–9.
25. Hare JM, Loh E, Creager MA, Colucci WS. Nitric oxide inhibits the
positive inotropic response to beta-adrenergic stimulation in humans
with left ventricular dysfunction. Circulation 1995;92:2198–203.
26. Paulus WJ, Vantrimpont PJ, Shah AM. Paracrine coronary endothe-
lial control of left ventricular function in humans. Circulation 1995;
92:2119–26.
27. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the
expression of plasminogen activator inhibitor-1 in cultured endothelial
cells: a potential link between the renin-angiotensin system and
thrombosis. J Clin Invest 1995;95:995–1001.
28. Drexler H. Endothelium as a therapeutic target in heart failure.
Circulation 1998;98:2652–5.
29. Genth-Zotz S, Zotz R, Geil S, Voigtla¨nder T, Meyer J, Darius H.
Recombinant growth hormone therapy in patients with ischemic
cardiomyopathy: effects on hemodynamics, left ventricular function,
and cardiopulmonary exercise capacity. Circulation 1999;99:18–21.
30. Fazio S, Sabatini D, Capaldo B, et al. A preliminary study of growth
hormone in the treatment of dilated cardiomyopathy. N Engl J Med
1996;334:809–14.
95JACC Vol. 39, No. 1, 2002 Napoli et al.
January 2, 2002:90–5 GH and Vascular Dysfunction in Heart Failure
